Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

We conducted a phase I study using midostaurin (25 or 50 mg orally twice daily), all-trans retinoic acid (ATRA) and CLAG chemotherapy to target multiple pathways in relapsed/refractory AML. 10 patients received the combination and no dose-limiting toxicities were observed. Two patients (22 %) achieved complete remission and 1 patient (11 %) achieved complete remission with incomplete count recovery. Pharmacokinetic data showed that the 25 mg dosing of midostaurin achieved therapeutic levels with no significant interaction between midostaurin and ATRA. With evidence of activity of ATRA in NPM1-mutated AML and midostaurin in FLT3-ITD AML, this combination warrants further investigation.

Original languageEnglish
Pages (from-to)272-278
Number of pages7
JournalInternational Journal of Hematology
Volume99
Issue number3
DOIs
StatePublished - Mar 2014

Keywords

  • AML
  • ATRA
  • CLAG
  • Midostaurin
  • Phase I
  • Targeted therapy

Fingerprint

Dive into the research topics of 'Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML'. Together they form a unique fingerprint.

Cite this